Bionas Signs new Sales Representative for the U.S. and Appoints Managing Director
In addition to serving current clients and attracting new ones, Dr. Haber will focus on client problems and needs and show how they could be solved or mitigated with Bionas products or services. Dr. Haber will team up with Dr. Michael Schulze, who has been appointed Managing Director, a position he will hold jointly with Dr. Ralf Ehret, founder of Bionas GmbH.
The Bionas® 2500 analyzing system, the company’s leading product, allows the simultaneous, label-free and high-content analysis of three metabolic parameters, such as acidification, oxygen consumption and adhesion of living cells. It gives a complete overview of the physiological state of cells and can be used to analyze different signal transduction pathways, allowing target validation studies at an early stage in the drug discovery process.
Bionas GmbH, located in Rostock, Germany, specializes in analyzing systems and services for in vitro profiling the metabolic activity of cells to understand cellular function. Bionas® 2500 analyzing system measures extracellular acidification, oxygen consumption and cell adhesion label-free and noninvasively. It can be applied to various cell types including primary cells and tissues. The readout is performed continuously and can be monitored online. Main applications include drug profiling, lead optimization, pharmacokinetics, early toxicology programs, ADME/Tox, chemosensitivity testing, toxicological testing of chemical substances (REACH) and cell culture monitoring and optimization.